

Review

Broadly Neutralizing Antibodies against HIV:
Back to BloodAmir Dashti,¹ Anthony L. DeVico,¹ George K. Lewis,¹ and Mohammad M. Sajadi^{1,2,*}

After years of continuous exposure to HIV envelope antigens, a minority of HIV-infected individuals develop a cognate polyclonal humoral response comprising very potent and extremely cross-reactive neutralizing antibodies [broadly neutralizing antibodies (bNAbs)]. Isolated bNAbs derived from memory B cell pools have been the focus of intense studies over the past decade. However, it is not yet known how to translate the features of bNAbs into practical HIV prevention methods. In this review, we attempt to seek insights from emerging information about the human broadly neutralizing plasma response as well as its frequency, clonal composition, specificity, potency, and commonality among infected subjects. We also consider how this information points to selecting and prioritizing certain epitope targets and strategies for HIV vaccine design.

The Broadly Neutralizing Antibody Response in HIV Infection

The prevention of HIV/AIDS (see [Glossary](#)) is a tall order for the human immune system. HIV is an integrating retrovirus that rapidly establishes permanent infection and cannot be naturally cleared thereafter. Once infection is established, HIV has an extreme capacity to evade immune responses by genetic variation [1]. Viral evolution translates to worldwide envelope sequence diversity, which clusters into genetic subtypes, or **clades**, at the population level. Therefore, an anti-HIV immune response must be very potent, sterilizing, and highly cross-reactive to have protective efficacy.

In theory, cross-reactive, neutralizing anti-HIV envelope antibodies [commonly termed broadly neutralizing antibodies (bNAbs)] could be used to prevent or treat HIV in a myriad of ways ([Figure 1](#)). It has been repeatedly shown that some HIV-infected subjects develop highly cross-reactive or near 'pan-neutralizing' antibody responses against various epitopes on the HIV envelope [2–6]. Further, a variety of monoclonal antibodies (mAbs) isolated from these individuals targeting different epitopes ([Figure 2](#)) exhibit impressive breadth and potency *in vitro* [5,7–10] and confer sterilizing protection in animal models of HIV infection [11–16]. Accordingly, bNAbs have been used as guides in attempts to engineer immunogens that might raise qualitatively similar humoral responses via vaccination (approaches termed 'reverse vaccinology' or 'rational design'; see [17–19]). Unfortunately, these approaches have not succeeded in reliably generating bNAb responses, or in producing an effective **neutralization**-based HIV vaccine.

Despite tremendous progress, more information may be needed to effectively use the features and targets of broadly neutralizing responses for prevention. Molecular information concerning the structure and function of isolated bNAbs abounds. However, knowledge of the conditions that surround the evolution and persistence of bNAbs in HIV-infected subjects will also inform the feasibility of vaccine design [20,21]. For example, rare bNAbs that demand aberrant circumstances to evolve and persist may be less practical design templates versus ones that are recurring across the spectrum of HIV-infected humans. Accordingly, in this

Highlights

A minority of HIV-infected subjects develop plasma-neutralizing responses with near-pan-neutralization breadth against heterologous virus strains. The development of such responses, depending on epitope specificity, is linked to infecting clade, viral load, duration of infection, and virus and host genetic factors.

New approaches allow extremely broad and potent bNAbs to be derived directly from human plasma responses.

In some cases, broadly neutralizing plasma activity traces to a single lineage of a few related bNAbs, representing a minority of the polyclonal anti-HIV envelope response. The cocirculation of poorly neutralizing/non-neutralizing anti-envelope antibodies does not abrogate the persistence and activities of the bNAbs.

Each class of known bNAb exhibits at least one 'atypical' trait (e.g., high somatic hypermutation, long HCDR3, and/or auto/polyreactivity).


Among bNAbs types, those against the CD4bs are seen more frequently, share common features among diverse subjects, and exhibit extreme neutralization breadth and potency.

¹Divisions of Vaccine Research and Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA

²Department of Medicine, Baltimore VA Medical Center, Baltimore, MD 21201, USA

*Correspondence: msajadi@ihv.umaryland.edu (M.M. Sajadi).

Potential uses for HIV-1 bNAbs




Trends in Molecular Medicine

Figure 1. Potential Uses for HIV-1 Broadly Neutralizing Antibodies (bNAbs). Abbreviations cART, combination antiretroviral therapy.

review we address the knowns and unknowns surrounding HIV bNAb responses that are detected in circulation.

The Basic View of HIV Neutralizing Activity

Direct neutralizing activity amounts to the inactivation of an HIV **virion** via the binding of an anti-envelope antibody, preventing viral attachment/entry. Thus, an antibody's direct neutralizing activity does not require Fc-mediated functions, although engagement with cell surface **Fc**



Trends in Molecular Medicine

Figure 2. Epitopes Targeted by Broadly Neutralizing Antibodies (bNAbs) on the HIV BG505 Trimer.

The HIV-1 gp120 is shown in light gray and HIV-1 gp41 in gray. The glycosylation throughout the trimer (glycan shield) is represented by green residues. The following colors were used for the epitopes: orange (V3-glycan), light blue (V2-glycan), dark blue (CD4bs), yellow (subunit interface), and purple (fusion peptide). Epitope residues for PGT145 (V2-glycan), PGT 121 (V3-glycan), 8ANC19 (subunit interface), and PGT 151 (fusion peptide) were obtained from [127], and N49P7 (CD4bs) was obtained from [7].

Glossary

Autoreactive: antibody having this trait are those with the ability to bind to self-antigens.

bNAbs: a type of antibody (directed at different epitopes) that arises in some HIV patients that are able to neutralize the majority of known HIV strains. These antibodies harbor unusual traits such as high somatic hypermutation, long HCDR3s, and auto/polyreactivity.

CD4 binding site: the part of HIV-1 envelope that binds to the CD4 receptor, which initiates viral entry. Antibodies which bind to the CD4 binding site of gp120 are termed anti-CD4bs antibodies.

Clade: subtype; HIV-1 is made up of three groups (M, N, and O), with Group M representing the vast majority of HIV strains worldwide. Group M is made up of many clades, with Clades A, B, and C being the most predominant, followed by other clades and between-clade recombinants.

Elite controller: rare HIV-infected individuals who can naturally suppress viral replication of HIV in their bodies to extremely low levels.

Elite neutralizer: rare HIV-infected individuals whose serum or plasma immunoglobulin can neutralize a majority of known HIV strains.

Fc receptor: receptor on the surface of certain cells (such as B cells, NK cells, macrophages, neutrophils, and mast cells) that recognizes the Fc portion (constant region) of an antibody.

gp120: glycoprotein 120; one of the proteins (along with gp41) making up the HIV envelope. gp120 is made up of five constant domains (labeled C1–C5) and variable domains or loops (labeled V1–V5).

HIV: a positive-sense single-stranded retrovirus covered with a viral envelope composed of trimers consisting of gp120 and gp41 proteins.

HIV envelope: the viral envelope of HIV, which is punctuated by spikes, each one made of three gp120s and gp41s, forming a heterodimer.

Neutralization: the ability of an antibody to prevent viral attachment, entry, and/or infection of otherwise susceptible cells without engagement of Fc-mediated effector functions. In HIV this occurs with inactivation of a

receptor is probably unavoidable and even beneficial *in vivo*. All known antibodies that neutralize HIV bind to the viral envelope trimer at either the surface antigen, gp120, or the transmembrane protein, gp41 [22,23]. Both proteins can be targeted for neutralization before and after attachment to host cells [5,24–29].

Historically, HIV neutralizing activity has been assessed in a wide variety of *in vitro* assays. Primary T cells [30–33], primary macrophages [34], and various immortalized cell lines [35,36] have been used as target cells for either primary viruses grown in activated human CD4⁺ T cells or cell line–adapted viruses. Other assay formats mix infected and uninfected cells to measure neutralization of cell–cell virus transmission [37]. More recently developed assays use pseudotyped viruses that express the envelopes of various HIV strains. Currently, the dominant assay of this sort mixes pseudotyped viruses with engineered HeLa cells (TZM-bl) expressing the HIV receptor (CD4) and coreceptors (CXCR4 and CCR5). The target cells express luciferase signals after a single round of infection. This assay format is highly reproducible, relatively high-throughput, and amenable to validation [38,39]. It helped identify certain bNAbs as candidates for clinical development [8,9,40,41]. Overall, it must be recognized that the potencies of neutralizing antibodies may vary significantly according to assay format. For example, neutralizing antibodies generally show lower potencies in assays using wild-type viruses and/or primary CD4⁺ T cells as targets versus cell line–based assays with pseudoviruses [42].

Neutralization assay development has also involved a strategy of sorting viruses into ‘tiers’ based on their sensitivity to selected monoclonal neutralizing antibodies or reference from HIV-infected plasma samples [43]. The Tier 1 class comprises viruses with the greatest and most frequent sensitivity to neutralization, whereas Tier 2 viruses exhibit intermediate sensitivity and Tier 3 viruses the least sensitivity. These distinctions are somewhat arbitrary, as neutralization sensitivity follows a continuum among viruses [43], and there have been recent attempts to account for this [44]. Nevertheless, the tier system has been used for evaluating neutralizing antibody breadth and potency. Antibodies that cover all tiers *in vitro* are rare and highly cross-reactive. As such they are typically deemed to be superior members of their class.

Broadly Neutralizing Human Antibodies: What’s Out There?

Over the years a host of neutralizing mAbs have been recovered from HIV-infected subjects using a variety of methods [45–50]. The advent, circa 2009, of single-cell sorting with HIV envelope antigens, coupled with powerful new tools for sequencing immunoglobulin genes, significantly expanded the array of available antibodies and identified a collection of new epitopes and/or binding site details [5,8–10,41,51,52].

The properties of bNAbs inform the identification of vulnerable domains on the HIV envelope and reveal what humans are capable of producing. But faced with so many choices, which epitopes and antibodies do we really care about? The simple answer is that the most desirable antibodies will be the most potent and broadly reactive ones. However, there are some important nuances to consider.

Gauging neutralization breadth demands some sort of rubric. A simple tally of neutralized strains is insufficient: one could simply line up and test a wide array of neutralization-sensitive ‘Tier 1’ viruses (see discussion earlier) to secure a large total. Therefore, neutralization breadth is currently assessed using panels of viruses representing multiple clades and neutralization tiers (see discussion earlier). Antibodies are typically judged as broadly neutralizing if they exhibit some capacity to reach across clades and harder to neutralize Tier 2 and 3 viruses.

virion via the binding of an anti-envelope antibody. The outcome of the interaction is direct abrogation of envelope function (e.g., host receptor attachment).

Polyreactive: antibody having this trait are those with the ability to bind to multiple antigens.

Somatic hypermutation (SHM): the process of mutation affecting the variable region of B cell receptors (BCRs) in germinal center B cells undergoing affinity maturation, leading to higher affinity BCR and antibodies.

Viremia: the amount of virus in the blood. In HIV-1 infection, this can vary approximately 7 logs (10⁰–10⁷ HIV-1 RNA copies/ml), with the mean level in chronic infection (postacute infection and pre-AIDS) between 10⁴ and 10⁵ HIV-1 RNA copies/ml.

Virion: a complete virus particle (infective form of a virus outside a host cell, with a core of RNA or DNA and a capsid).

As it stands, mAbs directed against the **CD4 binding site** (CD4bs) on **gp120** and the 10E8 epitope in the membrane proximal region of gp41 exhibit superior cross-clade, cross-tier breadth, and potency (Table 1). Several anti-CD4bs mAbs neutralize all viruses in routine test panels and assays [7]. The least (albeit still impressive) breadth is observed with bNAbs against epitopes containing glycan arrays on the gp120 V1/V2 loop, gp120 V3 loop, and the gp120–gp41 interface, although these bNAbs tend to have more potency than those with more breadth (Table 1).

Interepitope differences in neutralization breadth and potency reveal some intriguing details. Notably, the breadth of certain bNAbs are restricted by clade-specific holes in coverage. Anti-V3-glycan neutralizing antibodies tend to be resistant to CRF01_AE viruses [53]. The anti-

Table 1. Potency and Neutralization of bNAbs

mAb	Epitope	% Neutralization breadth	Potency (IC ₅₀ µg/ml)	Potency (IC ₉₀ µg/ml)	Refs
N49P6 ^a	CD4bs	100	0.31	0.71	[7]
N49P7 ^a	CD4bs	100	0.10	0.39	[7]
N49P11 ^a	CD4bs	100	1.98	10.64	[7]
N6 ^a	CD4bs	98	0.09	0.32	[7]
DH511-2	gp41	98	1.20	6.60	[52]
10E8 ^a	gp41	97	0.72	4.20	[7]
VRC07 ^a	CD4bs	92	0.11	0.39	[7]
12A12	CD4bs	92	0.24	1.13	[8]
3BNC117 ^a	CD4bs	90	0.09	0.31	[7]
N49P9 ^a	CD4bs	89	0.12	0.42	[7]
VRC01 ^a	CD4bs	88	0.25	0.95	[7]
NIH45-46 ^a	CD4bs	86	0.09	0.38	[7]
PG9 ^a	V1V2-glycan	85	0.11	0.30	[7]
VRC-CH33	CD4bs	83	0.07	0.34	[58]
PG16 ^a	V1V2-glycan	82	0.03	0.15	[7]
PGDM1400 ^a	V1V2-glycan	80	0.02	0.14	[7]
VRC-PG04	CD4bs	76	0.17	0.74	[58]
PGT145 ^a	V1V2-glycan	74	0.11	0.40	[7]
PGT151 ^a	Fusion peptide	66	0.01	0.02	[7]
8ANC195 ^a	Subunit interface	65	0.91	3.54	[7]
PGT121 ^a	V3-glycan	66	0.03	0.08	[7]
BG18	V3-glycan	64	0.01	0.04	[87]
3BNC55	CD4bs	63	0.57	2.28	[8]
35O22	Subunit interface	62	.03	Not determined	[88]
PGT128 ^a	V3-glycan	60	0.02	0.05	[7]
N60P1.1 ^a	CD4bs	59	1.71	6.88	[7]
CH103	CD4bs	59	7.08	5.15	[89]
10-1074 ^a	V3-glycan	57	0.05	0.16	[7]

^aNeutralization tested in the same panel in the same laboratory.

V1V2-glycan mAbs demonstrate poor activity against Clade B viruses [54]. Furthermore, the potencies of certain anti-V1V2-glycan bNAbs, exemplified by PG9, PG16, and PGT145 [55], suffer from 'incomplete neutralization', a phenomenon where maximal neutralization plateaus without ever reaching 100%. This phenomenon occurs due to existence of some virions that are already resistant to antibody neutralization, regardless of the concentration, leading to nonsigmoidal dose–response neutralization curves. In addition to the antiglycan antibodies, this was noted to be a problem for some anti-gp41 and anti-gp41–120 interface antibodies. Incomplete neutralization is thought to be a result of glycan heterogeneity, though it remains incompletely understood [55]. Perhaps because of this, bNAbs targeting the CD4 binding site seem to be less likely to show this phenomenon (an exception being b12) [55]. In any case, these characteristics are stark reminders of the capacity for HIV to evade the humoral immune system at all levels.

More encouraging data suggest that bNAbs share similar characteristics across multiple HIV-infected subjects, and thus restricted germline immunoglobulin gene usage across individuals could be targeted by a vaccine. Such commonality lowers the chances that the antibodies are products of rare, peculiar, and/or donor-specific circumstances. For example, anti-CD4bs bNAbs arise from VH1-2 (can be found in 95% of populations) [5,8,9] or VH1-46 germline Ig heavy genes [7,9,56] across source subjects. Although the light chain of VRC01-like bNAbs makes fewer contacts with gp120, they also arise from a limited set of germline genes [8]. The recent finding of public antibody clonotypes (antibodies from different individuals that have an identical or near-identical CDRH3) makes this all the more relevant [57], but it remains to be seen if this will hold true for anti-CD4bs antibodies.

Almost all anti-CD4bs bNAbs exhibit a high degree of **somatic hypermutation**, which is essential for their breadth and potency [7,8,58,59]. VRC01-like antibodies contact gp120 through the D loop, the CD4-binding loop, and the V5 region [10]. VH1-2*02-derived antibodies are conserved in Arg71HC, Trp50HC, Asn58HC, and Trp100BHC [60], and in the unusual short five-length amino acid CDRL3 which is needed to stabilize and establish contact with gp120 (V5 and loop D) [61,62]. This short CDRL3 is necessary to avoid the glycan at position N267 in the D loop of gp120 [63,64]. Anti-CD4bs mAbs with the most extensive breadth (N49P6, N49P7, and NIH45-46) lack the deletion in CDRH3, distinguishing them from VRC01 and related bNAbs. This feature allows mAbs N49P6 and N49P7 to bypass Phe43 pocket in the CD4 binding site of gp120 and access the highly conserved inner domain of the envelope, thus allowing extraordinary breadth [7].

About 50% of gp120 trimer masses consist of glycan, with most of them in the form of high-mannose glucans (incompletely processed glycan) [65,66]. Most but not all of the antiglycan bNAbs bind to gp120 at/or around the N332 supersite using their long CDRH3 to reach the protein surface of gp120 at the V3 region [40,41,67,68]. PGT121, PGT128, and 10-1074 are among the V3-glycan bNAbs that are highly dependent on the glycan at Positions 301 and 332 [40,41]. Anti-V1V2-glycan bNAbs are well known for their very long CDRH3 and acidic amino acids at the tip of the CDRH3 for their binding to the lysine-rich region of the V2 loop. Their binding to gp120 is dependent on the conformation of the trimeric form of gp120 [5,54].

The Frequencies and Complexities of the Broadly Neutralizing Plasma Responses

Most if not all HIV-infected humans mount a neutralizing response against their homologous viruses; infected subjects frequently exhibit responses that neutralize a limited range of Tier 1 viruses; responses that neutralize across clades and cover more neutralization-resistant viruses

are less prevalent [6,69,70]. In a cross-sectional study, Doria-Rose *et al.* [70] found that plasma responses in roughly 38% of subjects neutralized four of five selected test viruses, and that roughly 8% could neutralize Tier 2 viruses in a cross-clade panel. A cross-sectional study by Hraber *et al.* [71] observed that roughly 50% of infected subjects had circulating responses capable of neutralizing 50% of strains across clades in the TZM-bl format along a continuum of potency. Within this continuum are ‘**elite neutralizers**’, first defined by potent plasma activity against more than one pseudovirus within a clade group and across at least four clade groups [72]. In a global cross-sectional study, Simek *et al.* [72] found that only 1% of subjects had plasma responses that met these criteria. Among such persons, a smaller subset has plasma responses with near-pan-neutralizing breadth [7,10,52,73]. There is no clear evidence, however, that such responses control autologous viral replication in the host. Further, every known ‘elite neutralizer’ from which a bNAb has been derived harbors HIV replication. Such resistant strains may be rather common in the general HIV-infected population [74,75].

The aforementioned studies have logically progressed toward attempts to understand what types of circulating antibodies are responsible for ‘elite’ or pan-neutralizing plasma activity. To be sure, extremely broad and potent bNAbs with multiple utilities have been isolated from the memory B cell pools of elite neutralizers [8–10,41,73]. However, it has been shown that memory B cell and circulating anti-envelope antibody repertoires are discordant in HIV infection [76]. Accordingly, significant efforts have been applied toward direct deconvolution of plasma-neutralizing responses. Approaches toward this end have included neutralization assays with mutant viruses selectively sensitive or resistant to specific types of neutralizing antibodies [5,77–79], antigen-specific depletion of plasma [4,77,80], or bulk immunoglobulin fractionation [7,81–83]. Recently, Williams *et al.* [52] deconvoluted an anti-gp41 bNAb lineage from an African HIV-1 Clade C chronically infected individual from both memory B cell and plasma [52]. Sajadi *et al.* [7] combined single-cell sequencing of bone marrow plasma cells with protein sequencing of gp120-specific plasma antibodies [7] to provide a comprehensive picture of the circulating repertoire. The approach yielded a family of closely related, near-pan-neutralizing plasma antibodies (N49P6 and N49P7 in Table 1) from a subject with equally broad and potent plasma activity.

In view of the aforementioned studies, we may step back and ask: do broadly neutralizing plasma responses in one person stem from monoclonal, pauciclonal, or polyclonal (one, several, or many) antibodies? So far, the answer seems to be ‘all of the above’. In some cases broadly neutralizing plasma activity tracks to one or two lineages of highly related antibodies. In a study of plasma from 13 HIV-infected patients using a panel of mutant pseudoviruses, Walker *et al.* [84] demonstrated that broadly neutralizing plasma activity typically tracks to one or two epitope specificities. Similarly, Bonsignori *et al.* [85] found that two distinct specificities isolated from a single subject seemed to explain over 95% of the serum neutralization. Thus, very broad and potent plasma-neutralizing responses are unlikely to be monoclonal although they may be monospecific (i.e., comprising a swarm of related antibodies sharing a major epitope specificity) [7].

More intriguing are cases where the overall plasma-neutralizing profile cannot be explained by the limited number of specificities as the examples given earlier [7,80,81]. Scheid *et al.* [86] reported that diverse mixtures of anti-HIV envelope mAbs derived from memory B cells approached but could not recapitulate the full spectrum of plasma-neutralizing activity of the source subject [86]. In one elite neutralizer, a case was identified where no single bNAb found in plasma could explain more than 60% of the neutralization breadth in circulation [7]. Simple mixing of multiple broad and potent plasma bNAbs from this subject achieved no more than around 90% of the circulating neutralization breadth. Collectively, these findings present a mixed bag for HIV vaccine development. Observations linking broadly neutralizing plasma

activity with monoclonal or pauciclonal specificity are a potential boon, as practical translation is conceptually uncomplicated. Data indicating that a more complicated plasma milieu explains 'elite' neutralizing activity warrant further exploration.

A related question concerns whether circulating 'non-neutralizing' or poorly neutralizing antibodies abrogate the persistence and/or activity of bNAbs. Deconvolution of a near-pan-neutralizing plasma response showed that the anti-CD4 binding site antibody family responsible for plasma activity comprised a minority of the anti-gp120 repertoire, cocirculating along with a much larger population of non-neutralizing anti-gp120 antibodies [7]. The same situation was observed in this donor at multiple sampling times and also in another donor [7].

What Aspects of HIV Infection Promote Broad and Potent HIV Neutralizing Antibodies in Circulation?

Multiple studies [71,90–92] have shown duration of infection and chronic antigen exposure to be key factors for bNAb development. For unknown reasons, anti-gp120 responses tend to arise later than those against other HIV antigens, including gp41 (the median time for appearance of anti-gp41 and anti-gp120 IgG antibodies are 14 and 28 days, respectively) [93]. Anti-gp41 antibodies are thought to arise earlier than anti-gp120 because of engagement of pre-existing memory B cells that have been generated through contact with commensal microbiota. Nevertheless, neutralizing antibodies take several months to develop [36,94], and neutralization breadth takes a median of 2.5 years to first be detected [95]. The most broad and potent bNAbs manifest with unusually high levels of somatic hypermutation [96,97], reflecting the impact of prolonged antigenic stimulation. The prolonged time it takes to develop the bNAb response has profound implications for HIV vaccine development (potential number/amount of antigen exposure, as well as high hypermutation requirement).

Early germinal centers (GCs) are made up of highly diverse B cell clones [98], but clonal selection leads to the more homogeneous GCs, with affinity maturation constantly eliminating low-affinity antibodies and replacing them with higher-affinity antibodies. In the GC, other factors can be important as well. B cells reactive to gp41 antigen have been found to be present in the memory B cell pool of HIV-negative persons [99]. In certain other situations, different B cell lineages can work synergistically (viral escapes mutants against one antibody have been shown to have higher binding affinity to a second lineage) [100].

The magnitude of viral replication is an intriguing variable in bNAb development. Several studies indicated an association between high HIV-1 viral load and bNAb production [69,101–103]. However, no such relationship was reported elsewhere [6,102]. Some of this discrepancy may be due to varying definitions of bNAb activity between studies. Remarkably, Clade B 'elite neutralizers', reflect sustained, low-level **viremia** between 10^2 and 10^4 copies/ml [6]. In other words, many will also fall within the category of '**elite controllers**' or 'viremic controllers'. This trend is evident in many of the subjects from which bNAbs of different specificities have been derived: Donor 45 (VRC01, VRC07, NIH45-46), Donor N49 (N49P6, N49P7, N49P9), Donor N60 (N60P1.1, N60P2.1), Donor Z258 (N6), Patient 3 (3BNC117), N152 (10E8), EB354 (BG18), Patient 8 (8ANC195), and Donor Ch0210 (DH511-2) [7–10,15] (Table 2). In addition to low viral loads, these subjects (whose data is available) have relatively intact CD4 counts and prolonged duration of infection (Table 2). It may be that beginning of breadth noted in individuals with higher viral loads is due to an acceleration of the process initially (from higher viral loads), but that the bNAb production cannot be sustained due to CD4 cell loss and B cell dysfunction with disease progression. In those with extreme bNAb activity, sustained viral control and CD4 preservation over many years seem to be needed.

Table 2. Donor and Antibody Characteristics of bNAbs

MAb	Clade	Donor	Years after diagnosis	HIV-1 RNA copies/ml	CD4 (cells/ μ l)	Epitope	Ig gene family	Refs
N49P6 N49P7 N49P9	B	N49	20	7854	447	CD4bs	IGHV1-2*02 IGLV2-11*01/2 IGLV2-23*01/2/3	[7]
N6	B	Z258	21	996	733	CD4bs	IGHV1-2*02 IGKV1-33	[10]
3BNC117 3BNC55	B	Patient 3	Unknown (dx 2002)	880	427	CD4bs	IGHV1-2*02 IGKV1D-33	[8]
VRC01 VRC07 NIH45-46	B	Donor 45	18	<15 000	>500	CD4bs	IGHV1-2*02 IGKV3-11*01	[8,9,15]
BG18	B	EB354	28	454 (65–2520)	697 (554–1323)	V3-glycan	IGHV4-4 IGLV3-25	[87]
N60P1.1	B	N60	5	<400	888	CD4bs	IGHV1-2*02 IGKV1-5*01	[7]
10E8	B	N152	>20	3811	325	gp41	IGHV3-15*05 IGLV3-19*01	[73]
35O22	B	N152	>20	3811	325	Subunit interface	IGHV1-18*02 IGLV2-14*02, or IGLV2-23*01/2/3	[73]
8ANC195	B	Patient 8	Unknown (dx 1989)	<50	580	Subunit interface	IGHV1-69 IGKV1-5	[8]
PGT151	C	Donor 31	>3	Unknown	Unknown	Fusion peptide	IGHV3-30*04 IGKV2D-29*02	[113]
DH511-2	C	CH0210	Unknown	5180	Unknown	gp41	IGHV3-15 IGKV1-39	[52]
CH103	C	CH505	2.6	$\sim 10^4$ – 10^5	69–431	CD4bs	IGH4-59*01 IGL3-1*01	[89]
PGT145 PGDM1400	C	Donor 84	>3	Unknown	Unknown	V1V2-glycan	IGHV1-8*01 IGKV2-28*01/IGKV2D-28*01	[40,51]
PGT121 10-1074	A	Donor 17	>3	Unknown	Unknown	V3-glycan	IGHV4-59*01 IGLV3-21*02	[40,41,114]
PG9 PG16	A	Donor 24	>3	Unknown	Unknown	V1V2-glycan	IGHV3-33*05 IGLV2-14*01	[5]
VRC-CH33	A	CH0219	>3	Unknown	Unknown	CD4bs	IGHV1-2*02 IGK1-33*01	[58]
VRC-PG04	A/D	Donor 74	Unknown	Unknown	Unknown	CD4bs	IGHV1-2*02 IGK1-33*01	[58]
12A12	CRF02_AG	Patient 12	>3	Unknown	Unknown	CD4bs	IGHV1-2 IGKV1D-33	[8,84,115]
PGT128	CRF02_AG	Donor 36	>3	Unknown	Unknown	V3-glycan	IGHV4-39*07 IGLV2-8*01	[40]

The infecting clade of a patient seems to have a role in the types of bNAbs they can generate. In a study of patients from Malawi, South Africa, Holland, and the United States, broadly neutralizing anti-CD4bs antibodies (not necessarily bNAbs) were detected in 88% of all sera collected between 99 and 258 weeks post-HIV-1 infection [104]. However, the most broad and

potent CD4bs bNAbs have been isolated from Clade B-infected patients (Table 2). In comparison, anti-V1V2-glycan and anti-V3-glycan bNAbs have been isolated from non-Clade B subjects (Table 2). This finding has also been validated on the population level. In a study with over 4000 patients, Rusert *et al.* [90] found that antibodies targeting the CD4bs were associated with subtype B infection, whereas anti-V2-glycan antibodies were associated with non-B subtypes [90]. Thus, the infecting HIV clade can have implications on the type of bNAb produced, and this should be a factor when considering the design of an HIV vaccine that will generate bNAbs.

The qualitative aspects of the viral envelopes being presented over time should also influence whether or not anti-envelope responses become broadly neutralizing. Exposure to envelope diversity is a contributing factor, during early infection [103] or with superinfection with heterologous HIV strains [54,105]. By contrast, a recent report argues that certain transmitted viruses possess unique phenotypic and/or genotypic properties that imprint bNAb lineages into the humoral immune system at the time of exposure [106].

If bNAbs regularly arise in certain HIV-infected populations, HIV envelope evolution should manifest a temporal drift toward neutralization resistance in the same groups of people [1]. Longitudinal analyses of Clade B- and Clade C-infected cohorts indicate this may indeed be the case. Bunnik *et al.* [107] examined the neutralization sensitivities of viruses isolated from over 30 Clade B HIV-infected men having sex with men (MSM) $\leq$ 4 months after seroconversion between 1985–1989 and 2003–2006 [107]. Neutralization assays indicated an overall trend toward decreased neutralization sensitivity over time. Bouvin-Pley *et al.* [108] examined the neutralization sensitivities of viruses isolated from early/transmitted Clade B HIV envelope variants from 40 MSM during the period from 1997 to 2010. This study revealed a continuous, temporal drift toward decreased neutralization sensitivity to a number of anti-gp120 neutralizing mAbs, including ones directed against the CD4bs and variable loop glycans. In another study done in a Clade C-infected population, the envelopes showed increasing resistance over a 13-year period [109]. On a sobering note, the more recent, neutralization-resistant variants were not only fully replication competent but also less immunogenic for generating plasma-neutralizing responses [107,108]. It will be interesting to follow such population dynamics as efforts to use anti-CD4bs bNAbs for prevention and therapy progress worldwide.

Host factors could further contribute to bNAb development in HIV infection. Landais *et al.* [102] investigated the effects of age, geographic origin, gender, viral load, CD4 T cell count, virus subtypes, and human leukocyte antigen (HLA) types on the development of neutralization breadth in patients from Eastern and Southern Africa. They found no detectable influence of gender, age, and/or geographic origin on the development of bNAb breadth. However, in several studies in infants, bNAbs appear to develop differently than adults. In a recent study, over 75% of children less than 6 years of age were able to neutralize a panel of 16 viruses, compared with only 19% of adults [110]. In another study, 20 of 28 infants less than 1 year of age developed cross-clade neutralizing antibody, some within 1 year of becoming infected [111]. Interestingly, children appear to routinely develop bNAbs against more than one epitope [112]. Whether this may be due to a function of a more intact immune system [110] or something specific in the developing immune system is still not known.

What Impedes the Generation and Circulation of Broad and Potent HIV Neutralizing Antibodies?

HIV bNAbs have been frustratingly difficult to raise in most mammals. Circa 2005, Haynes *et al.* [116] recognized that the broadly neutralizing mAbs 2F5 and 4E10, reactive with the membrane

Clinician's Corner

Most individuals with HIV infection make type-specific neutralizing antibody, capable of only neutralizing their own infecting clade of virus. Although a substantial portion of HIV-infected individuals do make some cross-reactive antibodies (to different clades) by several years after infection, only a minority of HIV-infected individuals (1%) make bNAbs that are potent enough to neutralize most strains from different clades around the world.

The study of the bNAb response as it occurs in circulation and the factors that lead to the development of such a response are intensive areas of study. Some factors that affect bNAb development are duration of HIV infection, amount of circulating virus, infecting clade, and viral diversity.

Currently, bNAbs are being used as templates for designing an HIV vaccine, and being evaluated as a potential therapy that can prevent, treat, or 'cure' HIV infection.

bNAbs are known to target several different epitopes on the HIV envelope, including CD4bs, V1V2-glycan, V3-glycan, gp41, and the gp41-gp120 interface. Besides the difference in epitopes, bNAbs have different properties (gene family use, degree of somatic hypermutation, autoreactivity, polyreactivity, potency, breadth, ability to completely neutralize virus, etc.), some of which appear among to be specific to the classes of bNAbs. The CD4bs bNAbs appear to have several characteristics that are favorable for clinical development compared with the others.

proximal external region (MPER) of gp41, were **auto/polyreactive** with cardiolipin and other mammalian antigens. Based on such findings, these investigators posited that immunization strategies routinely fail to raise circulating titers of neutralizing antibodies against MPER or other neutralizing epitopes because the parental B cells are auto/polyreactive. As such, they are deleted via natural immune-tolerance mechanisms [117]. This concept was initially met with strong skepticism and resistance [118]. Nevertheless, it was ultimately shown that B cell development in 2F5 VDJ knockin mice is blocked at the stage of pre-B to immature B cells, similar to what is observed in mice expressing known autoreactive B cell receptors against self-antigens [119]. Because of these elegant studies, the concept that bNAbs are linked to polyreactivity is a cornerstone for understanding both natural anti-HIV envelope responses and also why such immunity is so difficult to translate into a vaccine setting.

Ironically, some of the broadest and most potent HIV bNAbs are defined by characteristics that are typical of polyreactive antibodies such as long and hydrophobic CDRH3 domains. The 4E10 CDRH1 and CDRH3 domains can bind a variety of lipids (e.g., cardiolipin) potentially located in the vicinity of the gp41 MPER peptide. The near-pan-neutralizing anti-MPER mAb 10E8 is predicted to interact with membrane lipids via its CDRL1, CDRL2, and/or CDRH3 domains [120]. 10E8 was originally believed to not bind lipids [73]; however, it was later demonstrated that it binds cholesterol-rich bilayers [121]. Thus, the most broadly neutralizing anti-MPER neutralizing antibodies bind hybrid epitopes comprising multiple ‘self’ components. Anti-V1V2-glycan and anti-V3-glycan bNAbs also exhibit the connection between a long CDRH3 domain and polyreactivity. Fortunately, very broad and potent CD4bs bNAbs have been identified that are not apparently auto/polyreactive, according to standard measures [122].

Concluding Remarks

The translation of bNAb responses into clinical applications currently follows two paths, each with its own hurdles. The first path involves the rational optimization of bNAbs for direct use as antiviral agents. This exercise is largely technical, and success mainly hinges on the nature and performance of the antibodies themselves. Passive immunization of HIV-infected humans with single bNAbs has delivered only modest and transient clinical benefit, in part because of the emergence of resistant variants, some of which were present in subjects prior to antibody treatment [74,75,123]. Major efforts to broaden virus coverage, including the use of bispecific and mixtures of bNAbs, are underway [124]. The second path involves the use of bNAbs as templates for vaccine design. Here, success depends in part on whether the immune systems of most healthy humans are capable of generating the template bNAbs in an effective manner. Studies of circulating bNAb responses in HIV-infected subjects are helping to inform this issue, yielding contextual information not easily divulged from interrogations of memory B cell repertoires.

Two key lessons are emerging from studies of plasma-neutralizing responses. The first is that persistent, near-pan-neutralizing plasma activity can track to one or a few related antibody species comprised by the circulating polyclonal anti-Env response. These observations lend further support to the development of vaccines built around targeted epitopes. Notably, near-pan-neutralizing antibodies actively persist in plasma even as a minor part of a much larger repertoire of non-neutralizing anti-envelope antibodies. Specifically, circulating bNAbs are not ‘swamped out’ by a higher prevalence of other anti-Env specificities. This situation is additional good news for vaccine development, as it obviates concerns that near-pristine epitope specificity and selectivity are needed to elicit a bNAb response. A third lesson is that bNAb activities seen as most relevant to vaccine development (e.g., ones with near-pan-neutralizing activity) are infrequently detected in plasma from HIV-infected subjects. As these activities require immunoglobulins with atypical characteristics [5,7,9,51,52,86], emergence and

Outstanding Questions

Despite tremendous progress, efforts to develop bNAb-based HIV countermeasures remain hindered by several hurdles and gaps in knowledge. Questions addressable by studies of plasma-neutralizing responses include:

What host/virus conditions and characteristics support the generation and persistence of bNAb responses in plasma? Are they rare or recurring?

What explains broadly neutralizing plasma activity when it is not linked to one or few related bNAbs? Why do combinations of bNAbs from a single subject fail to replicate the full spectrum of plasma-neutralizing activity? What is the missing factor?

In elite neutralizers, what virus–host relationships are in play when ongoing, low-level plasma viral replication coexists with broad and potent plasma bNAbs? Can epitope–paratope relationships in these situations inform the design of engineered bNAbs with truly pan-neutralizing activity and/or inform improved envelope-based vaccine designs?

An expanded database of deconvoluted plasma-neutralizing responses should help resolve these questions, thus elucidating immune landscapes most likely to promote the development of pan-neutralizing antibody responses. Such information should provide valuable guideposts for developing optimized HIV countermeasures based on humoral immunity.

persistence in plasma could depend on peculiar characteristics of the host, the nature of the infecting HIV strain, coincident opportunistic infections, or other variables [54,96,97,99,100,106,122,125,126]. By contrast, it is promising that bNAbs with similar specificities and biochemical properties are repeatedly observed in diverse subjects [7,9,10]. These findings could mean that certain types of broadly neutralizing responses are not strongly dependent on rare, subject-specific immune stimulation/evolution events and may be achieved in healthy humans via vaccination (see Outstanding Questions).

Acknowledgments

The work on this article was supported by NIH 1R01AI110259-01A1 and VA Merit Award 1I01BX002358-01A1 to M.M.S.

References

- Lewis, G.K. *et al.* (2017) Survivors remorse: antibody-mediated protection against HIV-1. *Immunol. Rev.* 275, 271–284
- Sather, D.N. and Stamatatos, L. (2010) Epitope specificities of broadly neutralizing plasmas from HIV-1 infected subjects. *Vaccine* 28, B8–B12
- Li, Y. *et al.* (2009) Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. *J. Virol.* 85, 8954–8967
- Dhillon, A.K. *et al.* (2007) Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. *J. Virol.* 81, 6548–6562
- Walker, L.M. *et al.* (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. *Science* 326, 285–289
- Sajadi, M.M. *et al.* (2011) Correlation between circulating HIV-1 RNA and broad HIV-1 neutralizing antibody activity. *J. Acquir. Immune Defic. Syndr.* 57, 9–15
- Sajadi, M.M. *et al.* (2018) Identification of near-pan-neutralizing antibodies against HIV-1 by deconvolution of plasma humoral responses. *Cell* 173, 1783–1795.e14
- Scheid, J.F. *et al.* (2011) Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. *Science* 333, 1633–1637
- Wu, X. *et al.* (2010) Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. *Science* 329, 856–861
- Huang, J. *et al.* (2016) Identification of a CD4-binding-site antibody to HIV that evolved near-pan neutralization breadth. *Immunity* 45, 1108–1121
- Moldt, B. *et al.* (2012) Highly potent HIV-specific antibody neutralization *in vitro* translates into effective protection against mucosal SHIV challenge *in vivo*. *Proc. Natl. Acad. Sci. U. S. A.* 109, 18921–18925
- Shingai, M. *et al.* (2014) Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. *J. Exp. Med.* 211, 2061–2074
- Pegu, A. *et al.* (2014) Neutralizing antibodies to HIV-1 envelope protect more effectively *in vivo* than those to the CD4 receptor. *Sci. Transl. Med.* 6, 243ra88
- Saunders, K.O. *et al.* (2015) Sustained delivery of a broadly neutralizing antibody in nonhuman primates confers long-term protection against simian/human immunodeficiency virus infection. *J. Virol.* 89, 5895–5903
- Rudicell, R.S. *et al.* (2014) Enhanced potency of a broadly neutralizing HIV-1 antibody *in vitro* improves protection against lentiviral infection *in vivo*. *J. Virol.* 88, 12669–12682
- Saunders, K.O. *et al.* (2015) Broadly neutralizing human immunodeficiency virus type 1 antibody gene transfer protects non-human primates from mucosal simian-human immunodeficiency virus infection. *J. Virol.* 89, 8334–8345
- Medina-Ramirez, M. *et al.* (2017) Stabilized HIV-1 envelope glycoprotein trimers for vaccine use. *Curr. Opin. HIV AIDS* 12, 241–249
- de Taeye, S.W. *et al.* (2016) HIV-1 envelope trimer design and immunization strategies to induce broadly neutralizing antibodies. *Trends Immunol.* 37, 221–232
- Sanders, R.W. and Moore, J.P. (2017) Native-like Env trimers as a platform for HIV-1 vaccine design. *Immunol. Rev.* 275, 161–182
- Van Regenmortel, M.H. (2012) Basic research in HIV vaccinology is hampered by reductionist thinking. *Front. Immunol.* 3, 194
- Van Regenmortel, M.H.V. (2017) Immune systems rather than antigenic epitopes elicit and produce protective antibodies against HIV. *Vaccine* 35, 1985–1986
- Wibmer, C.K. *et al.* (2015) HIV broadly neutralizing antibody targets. *Curr. Opin. HIV AIDS* 10, 135–143
- Andrabi, R. *et al.* (2015) Identification of common features in prototype broadly neutralizing antibodies to HIV envelope V2 apex to facilitate vaccine design. *Immunity* 43, 95–973
- Gorny, M.K. *et al.* (2005) Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. *J. Virol.* 79, 5232–5237
- Wu, L. *et al.* (1996) CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. *Nature* 384, 179–183
- Trkola, A. *et al.* (1996) CD4-dependent: antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. *Nature* 384, 184–187
- Sullivan, N. *et al.* (1998) CD4-induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization. *J. Virol.* 72, 4694–4703
- Burton, D. *et al.* (1994) Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. *Science* 266, 1024–1027
- Ray, K. *et al.* (2014) Antigenic properties of the HIV envelope on virions in solution. *J. Virol.* 88, 1795–1808
- Brown, B.K. *et al.* (2008) Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models. *Virology* 375, 529–538
- D'Souza, M.P. *et al.* (1991) Evaluation of monoclonal antibodies to HIV-1 by neutralization and serological assays: an international collaboration. Collaborating Investigators. *AIDS* 5, 1061–1070
- D'Souza, M.P. *et al.* (1997) Evaluation of monoclonal antibodies to human immunodeficiency virus type 1 primary isolates by neutralization assays: performance criteria for selecting candidate antibodies for clinical trials. AIDS Clinical Trials Group Antibody Selection Working Group. *J. Infect. Dis.* 175, 1056–1062
- Nara, P.L. *et al.* (1987) Simple, rapid, quantitative, syncytium-forming microassay for the detection of human immunodeficiency virus neutralizing antibody. *AIDS Res. Hum. Retroviruses* 3, 283–302
- Ruppach, H. *et al.* (2000) Human immunodeficiency virus (HIV)-positive sera obtained shortly after seroconversion neutralize

- autologous HIV type 1 isolates on primary macrophages but not on lymphocytes. *J. Virol.* 74, 5403–5411
35. Polonis, V.R. *et al.* (2008) Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. *Virology* 375, 315–320
 36. Wei, X. *et al.* (2003) Antibody neutralization and escape by HIV-1. *Nature* 422, 307–312
 37. Reh, L. *et al.* (2015) Capacity of broadly neutralizing antibodies to inhibit HIV-1 cell-cell transmission is strain- and epitope-dependent. *PLoS Pathog.* 11, e1004966
 38. Montefiori, D.C. (2009) Measuring HIV neutralization in a luciferase reporter gene assay. *Methods Mol. Biol.* 485, 395–405
 39. Sarzotti-Kelsoe, M. *et al.* (2014) Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. *J. Immunol. Methods* 409, 131–146
 40. Walker, L.M. *et al.* (2011) Broad neutralization coverage of HIV by multiple highly potent antibodies. *Nature* 477, 466–470
 41. Mouquet, H. *et al.* (2012) Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. *Proc. Natl. Acad. Sci. U. S. A.* 109, E3268–E3277
 42. Cohen, Y.Z. *et al.* (2018) Neutralizing activity of broadly neutralizing anti-HIV-1 antibodies against clade B clinical isolates produced in peripheral blood mononuclear cells. *J. Virol.* 92, e01883-17
 43. Seaman, M.S. *et al.* (2010) Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. *J. Virol.* 84, 1439–1452
 44. Hraber, P. *et al.* (2018) A single, continuous metric to define tiered serum neutralization potency against HIV. *eLife* 7, e31805
 45. Robert-Guroff, M. *et al.* (1985) HTLV-III-neutralizing antibodies in patients with AIDS and AIDS-related complex. *Nature* 316, 72–74
 46. Weiss, R.A. *et al.* (1985) Neutralization of human T-lymphotropic virus type III by sera of AIDS and AIDS-risk patients. *Nature* 316, 69–72
 47. Purtscher, M. *et al.* (1994) A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. *AIDS Res. Hum. Retroviruses* 10, 1651–1658
 48. Zwick, M.B. *et al.* (2001) Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. *J. Virol.* 75, 10892–10905
 49. Hammond, P.W. (2010) Accessing the human repertoire for broadly neutralizing HIV antibodies. *mAbs* 2, 157–164
 50. Roben, P. *et al.* (1994) Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. *J. Virol.* 68, 4821–4828
 51. Sok, D. *et al.* (2014) Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. *Proc. Natl. Acad. Sci. U. S. A.* 111, 17624–17629
 52. Williams, L.D. *et al.* (2017) Potent and broad HIV-neutralizing antibodies in memory B cells and plasma. *Sci. Immunol.* 2, eaal2200
 53. Wang, H. *et al.* (2018) Evaluation of susceptibility of HIV-1 CRF01_AE variants to neutralization by a panel of broadly neutralizing antibodies. *Arch. Virol.* 163, 3303–3315
 54. Doria-Rose, N.A. *et al.* (2014) Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. *Nature* 509, 55–62
 55. McCoy, L.E. *et al.* (2015) Incomplete neutralization and deviation from sigmoidal neutralization curves for HIV broadly neutralizing monoclonal antibodies. *PLoS Pathog.* 11, e1005110
 56. West, A.P., Jr. *et al.* (2012) Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120. *Proc. Natl. Acad. Sci. U. S. A.* 109, E2083–E2090
 57. Setliff, I. *et al.* (2018) Multi-donor longitudinal antibody repertoire sequencing reveals the existence of public antibody clonotypes in HIV-1 infection. *Cell Host Microbe* 23, 845–854.e6
 58. Wu, X. *et al.* (2011) Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. *Science* 333, 1593–1602
 59. Zhou, T. *et al.* (2010) Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. *Science* 329, 811–817
 60. Scharf, L. *et al.* (2013) Structural basis for HIV-1 gp120 recognition by a germ-line version of a broadly neutralizing antibody. *Proc. Natl. Acad. Sci. U. S. A.* 110, 6049–6054
 61. Jardine, J.G. *et al.* (2015) HIV-1 vaccines. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. *Science* 349, 156–161
 62. Burton, D.R. and Hangartner, L. (2016) Broadly neutralizing antibodies to HIV and their role in vaccine design. *Annu. Rev. Immunol.* 34, 635–659
 63. Zhou, T. *et al.* (2007) Structural definition of a conserved neutralization epitope on HIV-1 gp120. *Nature* 445, 732–737
 64. Jardine, J. *et al.* (2013) Rational HIV immunogen design to target specific germline B cell receptors. *Science* 340, 711–716
 65. Korber, B. *et al.* (2001) Evolutionary and immunological implications of contemporary HIV-1 variation. *Br. Med. Bull.* 58, 19–42
 66. Doores, K.J. *et al.* (2010) Envelope glycans of immunodeficiency viruses are almost entirely oligomannose antigens. *Proc. Natl. Acad. Sci. U. S. A.* 107, 13800–13805
 67. Calarese, D.A. *et al.* (2003) Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. *Science* 300, 2065–2071
 68. Kong, L. *et al.* (2013) Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. *Nat. Struct. Mol. Biol.* 20, 796–803
 69. Doria-Rose, N.A. *et al.* (2010) Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. *J. Virol.* 84, 1631–1636
 70. Doria-Rose, N.A. *et al.* (2009) Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. *J. Virol.* 83, 188–199
 71. Hraber, P. *et al.* (2014) Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. *AIDS* 28, 163–169
 72. Simek, M.D. (2009) Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. *J. Virol.* 83, 7337–7348
 73. Huang, J. *et al.* (2012) Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. *Nature* 491, 406–412
 74. Scheid, J.F. *et al.* (2016) HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. *Nature* 535, 556–560
 75. Bar, K.J. *et al.* (2016) Effect of HIV antibody VRC01 on viral rebound after treatment interruption. *N. Engl. J. Med.* 375, 2037–2050
 76. Guan, Y. *et al.* (2009) Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection. *Proc. Natl. Acad. Sci. U. S. A.* 106, 3952–3957
 77. Gray, E.S. *et al.* (2009) Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. *J. Virol.* 83, 8925–8937
 78. Davis, K.L. *et al.* (2009) High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination. *Virology* 387, 414–426
 79. Decker, J.M. *et al.* (2005) Antigenic conservation and immunogenicity of the HIV coreceptor binding site. *J. Exp. Med.* 201, 1407–1419
 80. Li, Y. *et al.* (2009) Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. *J. Virol.* 83, 1045–1059

81. Sajadi, M.M. *et al.* (2012) Signature biochemical properties of broadly cross-reactive HIV-1 neutralizing antibodies in human plasma. *J. Virol.* 86, 5014–5025
82. Sajadi, M.M. *et al.* (2016) Lambda light chain bias associated with enhanced binding and function of anti-HIV Env glycoprotein antibodies. *J. Infect. Dis.* 213, 156–164
83. Tomaras, G.D. *et al.* (2011) Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. *J. Virol.* 85, 11502–11519
84. Walker, L.M. *et al.* (2010) A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals. *PLoS Pathog.* 6, e1001028
85. Bonsignori, M. *et al.* (2012) Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine design. *J. Virol.* 86, 4688–4692
86. Scheid, J.F. *et al.* (2009) Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. *Nature* 458, 636–640
87. Barnes, C.O. *et al.* (2018) Structural characterization of a highly-potent V3-glycan broadly neutralizing antibody bound to natively-glycosylated HIV-1 envelope. *Nat. Commun.* 9, 1251
88. Huang, J. *et al.* (2014) Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface. *Nature* 515, 138–142
89. Liao, H.X. *et al.* (2013) Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. *Nature* 496, 469–476
90. Rusert, P. *et al.* (2016) Determinants of HIV-1 broadly neutralizing antibody induction. *Nat. Med.* 22, 1260–1267
91. Subbaraman, H. *et al.* (2018) Broadly neutralizing antibodies: what is needed to move from a rare event in HIV-1 infection to vaccine efficacy? *Retrovirology* 15, 52
92. Dugast, A.S. *et al.* (2017) Virus-driven inflammation is associated with the development of bNAbs in spontaneous controllers of HIV. *Clin. Infect. Dis.* 64, 1098–1104
93. Tomaras, G.D. *et al.* (2008) Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. *J. Virol.* 82, 12449–12463
94. Aasa-Chapman, M.M. *et al.* (2004) Development of the antibody response in acute HIV-1 infection. *AIDS* 18, 371–381
95. Mikell, I. *et al.* (2011) Characteristics of the earliest cross-neutralizing antibody response to HIV-1. *PLoS Pathog.* 7, e1001251
96. Kwong, P.D. and Mascola, J.R. (2012) Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. *Immunity* 37, 412–425
97. Klein, F. *et al.* (2013) Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. *Cell* 153, 126–138
98. Tas, J.M. *et al.* (2016) Visualizing antibody affinity maturation in germinal centers. *Science* 351, 1048–1054
99. Liao, H.X. *et al.* (2011) Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. *J. Exp. Med.* 208, 2237–2249
100. Gao, F. *et al.* (2014) Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies. *Cell* 158, 481–491
101. Pereyra, F. *et al.* (2008) Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. *J. Infect. Dis.* 197, 563–571
102. Landais, E. *et al.* (2016) Broadly neutralizing antibody responses in a large longitudinal sub-Saharan HIV primary infection cohort. *PLoS Pathog.* 12, e1005369
103. Piantadosi, A. *et al.* (2009) Breadth of neutralizing antibody response to human immunodeficiency virus type 1 is affected by factors early in infection but does not influence disease progression. *J. Virol.* 83, 10269–10274
104. Lynch, R.M. *et al.* (2012) The development of CD4 binding site antibodies during HIV-1 infection. *J. Virol.* 86, 7588–7595
105. Williams, K.L. *et al.* (2018) Superinfection drives HIV neutralizing antibody responses from several B cell lineages that contribute to a polyclonal repertoire. *Cell Rep.* 23, 682–691
106. Kouyos, R.D. *et al.* (2018) Tracing HIV-1 strains that imprint broadly neutralizing antibody responses. *Nature* 561, 406–410
107. Bunnik, E.M. *et al.* (2010) Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level. *Nat. Med.* 16, 995–997
108. Bouvin-Pley, M. *et al.* (2013) Evidence for a continuous drift of the HIV-1 species towards higher resistance to neutralizing antibodies over the course of the epidemic. *PLoS Pathog.* 9, e1003477
109. Rademeyer, C. *et al.* (2016) Features of recently transmitted HIV-1 clade C viruses that impact antibody recognition: implications for active and passive immunization. *PLoS Pathog.* 12, e1005742
110. Muenchhoff, M. *et al.* (2016) Nonprogressing HIV-infected children share fundamental immunological features of nonpathogenic SIV infection. *Sci. Transl. Med.* 8, 358ra125
111. Goo, L. *et al.* (2014) Early development of broadly neutralizing antibodies in HIV-1-infected infants. *Nat. Med.* 20, 655–658
112. Ditse, Z. *et al.* (2018) HIV-1 subtype C-infected children with exceptional neutralization breadth exhibit polyclonal responses targeting known epitopes. *J. Virol.* 92, e00878-18
113. Falkowska, E. *et al.* (2014) Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. *Immunity* 40, 657–668
114. Mouquet, H. *et al.* (2011) Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses. *PLoS One* 6, e24078
115. Zhou, T. *et al.* (2013) Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. *Immunity* 39, 245–258
116. Haynes, B.F. *et al.* (2005) Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. *Science* 308, 1906–1908
117. Haynes, B.F. *et al.* (2005) Antibody polyspecificity and neutralization of HIV-1: a hypothesis. *Hum. Antibodies* 14, 59–67
118. Scherer, E.M. *et al.* (2007) Difficulties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity. *AIDS* 21, 2131–2139
119. Verkoczy, L. *et al.* (2010) Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance. *Proc. Natl. Acad. Sci. U. S. A.* 107, 181–186
120. Irimia, A. *et al.* (2016) Crystallographic identification of lipid as an integral component of the epitope of HIV broadly neutralizing antibody 4E10. *Immunity* 44, 21–31
121. Chen, J. *et al.* (2014) Mechanism of HIV-1 neutralization by antibodies targeting a membrane-proximal region of gp41. *J. Virol.* 88, 1249–1258
122. Bonsignori, M. *et al.* (2016) Maturation pathway from germline to broad HIV-1 neutralizer of a CD4-mimic antibody. *Cell* 165, 449–463
123. Caskey, M. *et al.* (2015) Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. *Nature* 522, 487–491
124. Padte, N.N. *et al.* (2018) Engineering multi-specific antibodies against HIV-1. *Retrovirology* 15, 60
125. Mouquet, H. and Nussenzweig, M.C. (2012) Polyreactive antibodies in adaptive immune responses to viruses. *Cell Mol. Life Sci.* 69, 1435–1445
126. Liu, M. *et al.* (2015) Polyreactivity and autoreactivity among HIV-1 antibodies. *J. Virol.* 89, 784–798
127. Chuang, G.Y. *et al.* (2019) Structural survey of broadly neutralizing antibodies targeting the HIV-1 Env trimer delineates epitope categories and characteristics of recognition. *Structure* 27, 196–206.e6